Formulary Search Results for: CALCIUM AND VITAMIN D
4.9.1 Dopaminergic drugs used in Parkinson’s disease - View Category
Restrictions:
Restricted to specialist use only for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.
6.1.2.2 SGLT2 Inhibitors - View Category
Restrictions:
Restricted to use only in adult patients for whom a combination of dapagliflozin and metformin is appropriate and who have demonstrated compliance issues with the separate constituents.
Prescribing Notes:
NHSGGC Diabetes Guidelines click here
7.3.2.1 Oral progestogen-only contraceptives - View Category
7.4.1 Drugs for urinary retention - View Category
Restrictions:
Restricted to specialist initiation.
Prescribing Notes:
Only suitable for patients with enlargement of the prostate.
7.1.1.0 Prostaglandins and oxytocics - View Category
8.1.5 Other antineoplastic drugs - View Category
Restrictions:
Restricted to specialist use in accordance with regional protocols [NHS network access required] for the following indications:
- Lung cancer:
- As monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 (programmed cell death ligand 1) on ≥1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.
- In combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
- Biliary tract cancer: In combination with gemcitabine and cisplatin for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer.
- Endometrial cancer: In combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with:
- durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)
- durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).
- Liver cancer: In combination with tremelimumab for the first-line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).
10.2.2 Skeletal muscle relaxants - View Category
10.2.2 Skeletal muscle relaxants - View Category
10.2.2 Skeletal muscle relaxants - View Category
Restrictions:
Restricted to specialist use for treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
Prescribing Notes:
Patients commencing treatment should be reviewed via a formal assessment conducted by the specialist service at 4 weeks. Treatment should be discontinued at that point if a clinically significant improvement is not seen. Patients should also continue to be reviewed regularly thereafter to ensure continuing benefit.
8.1.5 Other antineoplastic drugs - View Category
Restrictions:
Restricted to specialist use in accordance with regional protocols [NHS network access required] for:
- Monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.
- In combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.
Prescribing Notes:
Non-formulary indications that have not been recommended by SMC for use in NHS Scotland:
- In combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.